Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1601-1611

  Aroda, Vanita R ^a,b,c   Knowler, William C ^d   Crandall, Jill P ^e   Perreault, Leigh ^f   Edelstein, Sharon L ^c   Jeffries, Susan L ^g   Molitch, Mark E ^h   Pi Sunyer, Xavier ⁱ   Darwin, Christine ^j   Heckman Stoddard, Brandy M ^k   Temprosa, Marinella ^c   Kahn, Steven E ^l,m   Nathan, David M ^n,o  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^m UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Diabetes prevention; DPP; DPPOS; Impaired glucose tolerance (IGT); Metformin; Prediabetes; Review

Indexed keywords

ACARBOSE; GLUCOSE; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; VALSARTAN; VOGLIBOSE; ANTIDIABETIC AGENT;

ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; COST CONTROL; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGLYCEMIA; EXERCISE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH ECONOMICS; HUMAN; INCIDENCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MALIGNANT NEOPLASM; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME; IMPAIRED GLUCOSE TOLERANCE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PREDIABETIC STATE;

EID: 85026778634     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4361-9     Document Type: Review

References (52)

1. Diabetes Prevention Program Research Group (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634
2. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
3. Jarrett RJ, Keen H, Fuller JH, McCartney M (1979) Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”). Diabetologia 16:25–30
4. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G (1980) Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41–49
5. Keen H, Jarrett RJ, McCartney P (1982) The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 22:73–78
6. Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544
7. Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
8. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE et al (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677–1686
9. Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3:866–875
10. Aroda VR, Ratner RE (2012) Interventional trials to prevent diabetes: diabetes prevention Program. In: LeRoith D (ed) Prevention of type 2 diabetes: from science to therapy. Springer, New York, pp 143–166
11. American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197
12. Walker EA, Molitch M, Kramer MK et al (2006) Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29:1997–2002
13. Diabetes Prevention Program Research Group, Hamman RF, Horton E et al (2015) Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes 64:989–998
14. Ratner RE, Christophi CA, Metzger BE et al (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 93:4774–4779
15. Aroda VR, Christophi CA, Edelstein SL et al (2015) The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program Outcomes Study 10-year follow-up. J Clin Endocrinol Metab 100:1646–1653
16. Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26:977–980
17. Lachin JM, Christophi CA, Edelstein SL et al (2007) Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 56:1153–1159
18. Kitabchi AE, Temprosa M, Knowler WC et al (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 54:2404–2414
19. DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281–303
20. Hundal RS, Krssak M, Dufour S et al (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063–2069
21. International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334
22. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69
23. Diabetes Prevention Program Research Group (2015) HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized clinical trial. Diabetes Care 38:51–58
24. Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250
25. Hivert MF, Jablonski KA, Perreault L et al (2011) Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes 60:1340–1348
26. Jablonski KA, McAteer JB, de Bakker PI et al (2010) Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the Diabetes Prevention Program. Diabetes 59:2672–2681
27. Diabetes Prevention Program Research Group (2009) Changes in albumin excretion in the Diabetes Prevention Program. Diabetes Care 32:720–725
28. Goldberg R, Temprosa M, Otvos J et al (2013) Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab 98:3989–3998
29. Goldberg RB, Temprosa MG, Mather KJ et al (2014) Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the Diabetes Prevention Program except in those who develop diabetes. Diabetes Care 37:2253–2260
30. Orchard TJ, Temprosa M, Goldberg R et al (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142:611–619
31. Ratner R, Goldberg R, Haffner S et al (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28:888–894
32. Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M et al (2013) Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 30:46–55
33. Goldberg RB, Aroda VR, Bluemke DA et al (2017) Effect of long-term metformin and lifestyle in the Diabetes Prevention Program and its outcome study on coronary artery calcium. Circulation doi:10.1161/CIRCULATIONAHA.116.025483
34. Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35:731–737
35. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675
36. Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 101:1754–1761
37. American Diabetes Association (2017) Prevention or delay of type 2 diabetes. Diabetes Care 40:S44–S47
38. International Diabetes Federation (2016) IDF diabetes atlas—7th edition, www.diabetesatlas.org/. Accessed 14 Feb 2017
39. Diabetes Prevention Program Research Group (2012) The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35:723–730
40. Hostalek U, Gwilt M, Hildemann S (2015) Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 75:1071–1094
41. Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077
42. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161
43. Kosaka K, Noda M, Kuzuya T (2005) Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152–162
44. Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297
45. Dream Trial Investigators, Gerstein HC, Yusuf S et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105
46. Dream Trial Investigators, Bosch J, Yusuf S et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562
47. Kawamori R, Tajima N, Iwamoto Y et al (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607–1614
48. Navigator Study Group, JJ MM, Holman RR et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490
49. Navigator Study Group, Holman RR, Haffner SM et al (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476
50. Zinman B, Harris SB, Neuman J et al (2010) Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376:103–111
51. DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115
52. le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389:1399–1409